HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.

Abstract
Twenty-five adult patients with previously untreated acute non-lymphocytic leukemia (ANLL) were treated with mitoxantrone (Mto) 12 mg/m2 daily by 30 minutes intravenous (IV) infusion for 3 days and cytosine arabinoside (Ara-C) 200 mg/m2 daily by continuous infusion for 7 days, as an induction therapy. After complete remission (CR) was observed, they were given two more courses of consolidation therapy which was as Mto 12 mg/m2 daily by 30 minutes IV infusion for one day, and Ara-C 200 mg/m2 daily by 30 minutes IV infusion for 5 days. CR was obtained in 18 of 25 patients (72%). Median remission duration was 294 days and length of survival was 366 days. 11 patients (44%) are still in remission. Myelosupression developed in all patients following induction therapy, but it was not observed after consolidation therapies. Non-hematological side-effects consisted of nausea, vomiting, alopecia, stomatitis, and transient elevation in liver enzymes. Our therapeutic responses are similar to those obtained by others.
AuthorsI Osman, U Akin, A Ismet, B Meral, A Hamdi, K Haluk
JournalHaematologia (Haematologia (Budap)) Vol. 27 Issue 2 Pg. 93-7 ( 1996) ISSN: 0017-6559 [Print] Netherlands
PMID14651226 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Cytarabine
  • Mitoxantrone
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bone Marrow Diseases (chemically induced)
  • Cytarabine (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Female
  • Gastrointestinal Diseases (chemically induced)
  • Humans
  • Leukemia, Myeloid, Acute (drug therapy)
  • Male
  • Middle Aged
  • Mitoxantrone (administration & dosage, adverse effects)
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: